ANI Pharmaceuticals (ANIP) Competitors $54.12 +0.77 (+1.44%) (As of 02:11 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ANIP vs. ACLX, ADMA, RARE, APLS, BHVN, SRRK, IMVT, RNA, OGN, and PTCTShould you be buying ANI Pharmaceuticals stock or one of its competitors? The main competitors of ANI Pharmaceuticals include Arcellx (ACLX), ADMA Biologics (ADMA), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS), Biohaven (BHVN), Scholar Rock (SRRK), Immunovant (IMVT), Avidity Biosciences (RNA), Organon & Co. (OGN), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry. ANI Pharmaceuticals vs. Arcellx ADMA Biologics Ultragenyx Pharmaceutical Apellis Pharmaceuticals Biohaven Scholar Rock Immunovant Avidity Biosciences Organon & Co. PTC Therapeutics ANI Pharmaceuticals (NASDAQ:ANIP) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, community ranking, profitability, analyst recommendations and risk. Do analysts rate ANIP or ACLX? ANI Pharmaceuticals presently has a consensus price target of $77.71, suggesting a potential upside of 45.15%. Arcellx has a consensus price target of $105.93, suggesting a potential upside of 40.47%. Given ANI Pharmaceuticals' higher possible upside, equities research analysts clearly believe ANI Pharmaceuticals is more favorable than Arcellx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ANI Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Arcellx 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.13 Does the media refer more to ANIP or ACLX? In the previous week, ANI Pharmaceuticals had 3 more articles in the media than Arcellx. MarketBeat recorded 6 mentions for ANI Pharmaceuticals and 3 mentions for Arcellx. ANI Pharmaceuticals' average media sentiment score of 1.16 beat Arcellx's score of 1.03 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcellx 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor ANIP or ACLX? ANI Pharmaceuticals received 366 more outperform votes than Arcellx when rated by MarketBeat users. However, 82.93% of users gave Arcellx an outperform vote while only 64.58% of users gave ANI Pharmaceuticals an outperform vote. CompanyUnderperformOutperformANI PharmaceuticalsOutperform Votes43464.58% Underperform Votes23835.42% ArcellxOutperform Votes6882.93% Underperform Votes1417.07% Do insiders & institutionals believe in ANIP or ACLX? 76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 96.0% of Arcellx shares are held by institutional investors. 12.7% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 6.2% of Arcellx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is ANIP or ACLX more profitable? ANI Pharmaceuticals has a net margin of -1.28% compared to Arcellx's net margin of -25.94%. ANI Pharmaceuticals' return on equity of 15.87% beat Arcellx's return on equity.Company Net Margins Return on Equity Return on Assets ANI Pharmaceuticals-1.28% 15.87% 6.88% Arcellx -25.94%-8.28%-5.21% Which has stronger valuation & earnings, ANIP or ACLX? ANI Pharmaceuticals has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioANI Pharmaceuticals$555.46M2.03$18.78M-$0.55-97.35Arcellx$155.82M26.17-$70.69M-$0.71-106.21 Which has more volatility and risk, ANIP or ACLX? ANI Pharmaceuticals has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. SummaryANI Pharmaceuticals beats Arcellx on 13 of the 19 factors compared between the two stocks. Ad ProsperityPubCrypto’s hidden gem + greatest crypto bull run in history = $$$?You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.Click Here to get the full details about Crypto’s Hidden Gem Get ANI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIP vs. The Competition Export to ExcelMetricANI PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.13B$6.61B$5.16B$9.10BDividend YieldN/A2.99%5.12%4.26%P/E Ratio-97.3510.6387.5117.12Price / Sales2.03194.281,136.45119.65Price / Cash9.2257.1643.2337.85Price / Book2.535.104.784.77Net Income$18.78M$151.83M$120.55M$225.50M7 Day Performance-5.00%-1.19%-1.64%-1.29%1 Month Performance-5.92%-4.73%14.04%0.45%1 Year Performance0.21%8.89%28.88%15.38% ANI Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIPANI Pharmaceuticals4.8428 of 5 stars$54.12+1.4%$77.71+43.6%-0.1%$1.14B$555.46M-98.40642ACLXArcellx2.9726 of 5 stars$84.54+0.9%$105.93+25.3%+40.3%$4.57B$155.82M-118.03130Positive NewsADMAADMA Biologics3.7713 of 5 stars$19.07+2.6%$21.25+11.4%+310.4%$4.51B$382.81M68.32530RAREUltragenyx Pharmaceutical4.5119 of 5 stars$46.30+1.1%$87.46+88.9%-6.9%$4.28B$434.25M-7.081,276Analyst ForecastAPLSApellis Pharmaceuticals4.4975 of 5 stars$33.51+1.0%$49.94+49.0%-42.5%$4.17B$396.59M-16.35702Positive NewsBHVNBiohaven3.6217 of 5 stars$40.59+5.5%$63.00+55.2%-9.5%$4.10B$462.51M-4.11239SRRKScholar Rock3.9955 of 5 stars$43.51+3.6%$40.43-7.1%+138.8%$4.07B$33.19M-17.86140Positive NewsIMVTImmunovant1.4579 of 5 stars$27.55+4.8%$47.89+73.8%-37.7%$4.04BN/A-11.84120RNAAvidity Biosciences2.178 of 5 stars$33.61+3.4%$63.60+89.2%+245.3%$4.01B$10.12M-11.28190Analyst ForecastAnalyst RevisionOGNOrganon & Co.4.8095 of 5 stars$14.74-3.7%$21.33+44.7%+4.8%$3.80B$6.26B2.9110,000PTCTPTC Therapeutics3.801 of 5 stars$47.67+2.8%$54.08+13.4%+67.5%$3.68B$937.82M-7.811,410 Related Companies and Tools Related Companies Arcellx Alternatives ADMA Biologics Alternatives Ultragenyx Pharmaceutical Alternatives Apellis Pharmaceuticals Alternatives Biohaven Alternatives Scholar Rock Alternatives Immunovant Alternatives Avidity Biosciences Alternatives Organon & Co. Alternatives PTC Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ANIP) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
